A  of adult dermatomyositis was described in oral prednisolone, and over the subsequent 4 weeks the British Journal of Rheumatology in 1992 by Pugh her CK fell to 96 IU/l with a resolution of symptoms et al. [ l ] . Subsequent developments in the patient's ( Fig. 1) . By increasing chlorambucil to 3 mg daily 3 illness highlight the difficulties in managing this conmonths later, it was possible to reduce the dose of dition.
prednisolone to a minimum of 10 mg/15 mg alternate In September 1989, a previously well 26-yr-old days whilst maintaining a good response. Because of woman presented with a 9 week history of myalgia concerns about potential long-term oncogenic sideand proximal myopathy. Her creatine kinase (CK ) effects, the dose of chlorambucil was reduced to 2 mg was 5000 IU/l. A muscle biopsy confirmed polymyosdaily in September of 1996, by which time she had a itis. Oral prednisolone was started at a dose of 40 mg cumulative dose of~1 g. daily. She responded well and her symptoms resolved.
About 4 weeks later, a gradual progressive deterioraThe CK fell to 436 IU/l within 10 weeks. When the tion occurred with muscle aches, skin rashes and dose of prednisolone was reduced to 20 mg daily, she dyspnoea. By December 1996, her CK had risen to relapsed. Second-line agents were therefore added.
1540 IU/l, and pulmonary function testing and repeat Unfortunately, the patient could tolerate neither high-resolution CT of the chest confirmed early fibmethotrexate nor oral cyclophosphamide due to liver rosing alveolitis once more. Despite repeated pulses of function abnormalities. Azathioprine caused gastroi.v. methylprednisolone (3 × 500 mg and 2 × 500 mg) intestinal disturbance.
and an increase of chlorambucil to 4 mg daily, the Remission was finally achieved with four 500 mg clinical response was small and short lived with a cyclophosphamide pulses given at intervals of 4 weeks, reduction of CK to 772 IU/l. A course of i.v. immunoand followed by 100 mg oral cyclophosphamide daily.
globulin infusions was therefore started in February Unfortunately, she relapsed 3 months later. She had 1997. She received three cycles of 2.0 g of VigamB/kg proximal and axial muscle weakness, dyspnoea on body weight at monthly intervals with very good slight exertion, an erythematous facial rash, a periresponse. After the first dose, her CK fell to 67 IU/l pheral synovitis with Gottren's papules and nailfold and since then all her symptoms have once again infarcts. Cyclosporin A was added to 40 mg oral resolved. Repeat pulmonary function testing showed prednisolone. Within 4 weeks, the skin lesions had improved gas transfer. It has been possible gradually resolved and muscle power had returned to normal.
to withdraw chlorambucil completely and at present The CK fell from 6160 to 151 IU/l.
she remains well on prednisolone 15 mg daily. Over the subsequent 11 months, the patient remained Dermatomyositis can be a difficult condition to treat. well on 10 mg or less of prednisolone with cyclosporin Systemic corticosteroids are the first choice of treatat a dose of 3 mg/kg. During this period, she became ment. About a quarter of patients either fail to respond increasingly dyspnoeic. A high-resolution CT scan of to steroids or develop steroid-related toxicity [2] . the chest confirmed early fibrosing alveolitis. She then Second-line agents are then added either alone, or in developed muscle weakness and a truncal erythematous combination with steroids. Failure of the disease to rash, and a pulse of i.v. methylprednisolone was given.
respond to second-line agents, and side-effects from Cyclosporin was stopped when she developed septithese drugs, can then be a problem. caemia after recurrent pneumonia.
A study of five patients with dermatomyositis unre-A total of six pulses of methylprednisolone sponsive to prednisolone or other immunosuppressive (2 × 500 mg and 4 × 750 mg) were given with no agents found that chlorambucil was an effective alternlasting remission between June 1994 and September ative [3] . Benefit was achieved within 6 weeks and 1995 (in addition to a daily dose of prednisolone of corticosteroids were discontinued in all but one patient. 20 mg). Another formulation of cyclosporin (NeoralB) Minimal chlorambucil toxicity, consisting of a mild was tried and was stopped following a further septileucopenia in two patients, was reported. Four of the caemic illness. By October 1995, the patient felt five patients were able to stop chlorambucil after 13-30 extremely unwell with florid symptoms of dermatomonths of treatment and the disease remained in myositis and a CK of 2646 IU/l.
Chlorambucil was started after careful counselling remission. at an initial dose of 2 mg daily, in addition to 30 mg Chlorambucil is an alkylating agent that inhibits DNA synthesis. It has a cytotoxic effect and suppresses the cell-mediated immune response. Both of these Submitted 4 April 1997; revised version accepted 3 September 1997. actions may be relevant to its role in dermatomyositis
